Polycystic Ovary Syndrome Treatment Market Trends & Revenue Growth the end of 2027

Research Nester released a report titled “Polycystic Ovary Syndrome Treatment Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global polycystic ovary syndrome treatment market in terms of market segmentation by drugs, by surgery, by distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Polycystic ovary syndrome is a hormonal condition in women of reproductive age and is characterized by the formation of multiple cysts in the ovaries. These cysts lead to obstruction of the ovulation pathway which eventually result in infertility among the affected women. The polycystic ovary syndrome treatment market is anticipated to record a CAGR of around 5% over the forecast period, i.e., 2019-2027.

Access Full Report, here: https://www.researchnester.com/sample-request-2069

The market is segmented by drugs, by surgery, by distribution channel and by region. Based on drugs, the market is further segmented into oral contraceptives, insulin-sensitizing drugs, antidepressants, anti-androgen drugs and others, out of which, the insulin-sensitizing drugs is estimated to hold the largest share in the polycystic ovary syndrome treatment market on account of higher demand of anti-diabetic drugs that decrease the hormone levels, thereby controlling PCOS as well as diabetes.

On the basis of geography, the market in North America is anticipated to hold the largest share in the PCOS treatment market on account of rising incidences of PCOS among women in the region. The rising awareness about the risks further raises the number of diagnosed cases which is estimated to promote the growth of the market during the forecast period. The market in Asia Pacific is estimated to witness the highest rate of growth in the upcoming years as a result of higher population in the region that gives rise to more cases of polycystic ovary syndrome.

Growing Awareness among Women about PCOS and Related Risks to Drive the Market Growth

According to Centers for Disease Control and Prevention, polycystic ovary syndrome is a common cause of infertility among women, affecting about 6% to 12% of females, i.e., around 5 million women in the United States. The growing cases of this disorder along with better diagnostic and treatment methods available are estimated to significantly boost the market growth. However, the medications for the treatment of PCOS alter the hormone levels in the body, causing various side effects including weight gain or loss, irregular menstruation and others. This is anticipated to hamper the market growth during the forecast period.

Get a PDF Sample for more detailed market insights: https://www.researchnester.com/sample-request-2069

This report also provides the existing competitive scenario of some of the key players of the global polycystic ovary syndrome treatment market which includes company profiling:

Millendo Therapeutics (MLND), Inc., Bayer AG (BAYN), Ferring B.V., Novartis AG (NOVN), EffRx Pharmaceuticals SA, Bristol-Myers Squibb Company (BMY), Teva Pharmaceutical Industries Ltd. (TEVA), GlaxoSmithKline (GSK), Mylan N.V. (MYL) and Sanofi S.A. (SAN).

The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global polycystic ovary syndrome treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.